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Psychosis secondary to lupus can lead to diagnos-
tic and therapeutic challenges particularly when
there is lack of autoantibodies. The condition is a
recognized feature within the spectrum of
ACR-deﬁned neuropsychiatric disorders occur-
ring in SLE.
1,2 As illustrated in the case reported
below, early diagnosis and treatment can lead to
favourable responses.
Case report
A 25-year-old Caucasian woman presented to the
emergency department via urgent GP referral
with a week-long history of deterioration in
mental state typical of acute psychosis. The
patient appeared extremelyanxious and disorient-
ated with paranoid delusions and bizarre ideation.
She mentioned hearing voices and being unable to
sleep oreat properly. She described hallucinations,
thought withdrawal and inability to carry out
simple tasks of daily living. She appeared to
have impaired memory and concentration and
lack of complete insight regarding her current
state although she was asking for help continually.
Prior to deterioration she had been ﬁt and well
with no history of drug use. She lived with her
parents and had a twin brother who was well.
There was no known family history of medical
or psychiatric illness and she was in a stable
relationship with her boyfriend.
The initial impression was of an acute psycho-
sis and she was discharged home on olanzapine
(5 mg twice daily) with plans for close community
mental health follow-up. However, within a few
days she was admitted acutely to the psychiatric
ward as her condition worsened and she devel-
oped Parkinsonian-like signs with stooped
posture, shufﬂing gait and masked facies. Her
thought processing had worsened with slowness
and increased paranoia. Physical examination
was normal including blood pressure (115/
70 mmHg) and fundoscopy. Initial biochemical
and microbiology screening was also normal
apart from a raised creatinine kinase level (1295
IU/L). There was no history of seizures. Ferritin
was normal and atypical infection screening
including toxoplasma, treponema pallidum,
lyme and HIV was negative. Autoantibody
screen, including ANA, ANCA, anti-cardiolipin,
serum ACE, immunoglobulins, dsDNA and
complement levels were negative. Thrombophilia
screen (including lupus anticoagulant) was
normal. A porphyria screen was also negative.
She was reviewed by a neurologist who was con-
cerned that she had an underlying organic cause
for the psychosis and may have developed extra-
pyrimidal side-effects from anti-psychotic
therapy. An MRI brain and lumbar puncture
were thus organized. The MRI revealed high
intensity signals in the subcortical white region
and left parietal region (Figure 1). CSF exami-
nation was normal. An incidental screening chest
radiograph revealed small pneumothoraces and
a subsequent high resolution computed tomogra-
phy scan of the thorax conﬁrmed these and
revealed small scattered pulmonary nodules
(Figure 2). Further testing showed the ck-mb
level was 23.7 (ref range 0–3.5). An echocardio-
gram was performed which showed right ventri-
cular hypokinesia.
The combination of psychosis with an MRI
appearance compatible with SLE and evidence of
lung and myocardial involvement led to a clinical
suspicion of of seronegative lupus. Despite
detailed screening no metabolic or infective
causes were evident. Thus, after extensive discus-
sion with neuroradiologists, neurologists and
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1lupus experts the decision was made to treat our
patient with pulsed cyclophosphamide (500 mg)
and methylprednisolone (250 mg). She received a
total of nine pulses as per the Lupus Institute
recommended regime for neurolupus (ﬁrst three
at weekly intervals then three at fortnightly inter-
vals and three at 3-weekly intervals). She tolerated
the infusions well. Clinically, progress was
initially slow but she did appear to improve in
terms of comprehension and concentration. She
was moved on to mycophenolate mofetil (1 g
twice daily) as maintenance treatment which she
also tolerated well. After six months inpatient
stay on the psychiatric ward she was discharged
home with day-care arrangements and reduced
anti-psychotic requirements (olanzapine 2.5 mg
nocte). Three days post discharge she had a wit-
nessed tonic-clonic seizure lasting approximately
one minute (no incontinence). She was thus com-
menced on an anti-epileptic (leviteracetam 500 mg
twice daily) on advice from neurologists. MRI
appearances remained unchanged and, importantly,
there were no new lesions. Clinically, our patient
thereafter made remarkable clinical progress and at
a recent outpatient review, nine months since the
initial psychotic episode, was reported to be almost
completely back to her usual self.
Discussion and conclusion
Our patient was unusual in her initial presentation
but psychosis can be one of the ﬁrst manifestations
of lupus. In a large series of SLE patients, psycho-
sis at the onset of disease was described in
one-third of cases.
3 It is usually reported occurring
in association with cutaneous and haematological
manifestations and active lupus markers, particu-
larly high titres of ANA and/or dsDNA anti-
bodies.
1 However, ANA negative lupus is a rare
but recognized condition with a reported preva-
lence between 5–8.9%.
4
ACR criteria for SLE can help with diagnosis
but are not necessary to make a diagnosis of neu-
ropsychiatric lupus. It is also recognized that the
spectrum of neurological conditions seen in
lupus is varied and there is still lack of agreement
on uniform criteria.
5,6
There is controversial evidence for autoanti-
bodies that may be detectable in the serum or CSF
of patients presenting with neuropsychiatric
lupus. These include anti-neuronal antibodies,
brain-lymphocyte cross-reactive antibodies, anti-
gangliosideantibodies,anti-ribosomalPantibodies
andanti-phospholipidantibodies.
7,8Testingforthe
Figure 1
MRI Brain (T2 FLAIR) showing high intensity
signal lesions within subcortical white matter
and single larger lesion in left parietal region
Figure 2
HRCT thorax showing small scattered pulmonary
nodules and pneumothoraces
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2ﬁrst three is not widely available. Reported preva-
lence of anti-P is highly variable and inﬂuenced
by factors such as ethnicity, sensitivity and speci-
ﬁcity of the assays used and timing of analysis
in relation to clinical event.
9,10 Our patient’s CSF
was sent to the USA for further analysis but
unfortunately due to technical problems it was
subsequently not possible to test it for speciﬁc
antibodies. She was negative for antiphospholipid
antibody which is reported in correlation with
lupus (thrombotic episodes involving cerebral
vasculature) although there are no convincing
data to support its usefulness in the diagnosis of
lupus psychosis.
11,12
MRI abnormalities
2,13 in SLE patients have a
varying reported prevalence (19–70%). T2
weighted images particularly with FLAIR sequen-
cing to dampen CSF signals are better for highlight-
ing areas of oedema. Focal neurological disease is
often associated with predominantly ﬁxed lesions
in the periventricular and subcortical white matter
within the territories of major cerebral blood
vessels. However, these are a non-speciﬁc ﬁnding
and also associated with hypertension, disease
duration and age-related small vessel changes.
Diffuse neuropsychiatric presentations are
often associated with transient subcortical white
matter lesions and patchy hyperintensities in
grey matter not conﬁned to major cerebral blood
ﬂow regions. Similar ﬁndings may occur in pos-
terior reversible encephalopathy syndrome
(PRES) which has been reported to occur in SLE.
Our patient presented with an altered mental
state and MRI ﬁndings which can occur in PRES
but did not manifest the more commonly reported
symptoms of headaches and visual disturbance.
She also had normal renal function and no
history of hypertensive episodes or prior use of
cytotoxic or immunosuppressive medication
which are other reported associations.
14
OtherimagingﬁndingsinSLEincludeinfarction,
venous sinus thrombosis and myelopathy. Single
photon emission computed tomography (SPECT)
scansaresensitiveinlupusinidentifyingabnormal-
ities in regional cerebral blood ﬂow. However,
abnormalities are seen in up to 50% of SLE patients
without neuropsychiatric manifestations.
2
There is limited information on the long-term
outcome of lupus psychosis. A follow-up study
commented on patients with severe psychotic
manifestations at onset having favourable
prognosis long term.
1 Currently, no standardized
treatmentexistsforlupuspsychosis.Corticosteroids
and various immunosuppressive regimes have
been reported as beneﬁcial.
1 Cyclophosphamide
has been shown to be more effective in neuropsy-
chiatric lupus compared to methylprednisolone
alone.
15 Plasmapheresis may be added in refrac-
tory cases.
16 There are case reports of successful
use of intravenous immunoglobulin.
17 Rituximab
has also been found effective in some cases.
18
Mycophenolate has been effective in our patient
in whom, due to gender and young age, long-term
cyclophosphamide would not be ideal. However,
there is limited evidence on its efﬁcacy in neuro-
psychiatric SLE
19 and use may thus currently be
restricted to those patients in whom cyclopho-
sphamide is contraindicated or ineffective.
20
A small open label study has shown azathioprine
to be useful in maintenance treatment of lupus
psychosis following induction therapy with cyclo-
phosphamide and steroids.
21
In summary, our case proved to be a diagnostic
and therapeutic challenge but ultimately led to a
positive outcome for all involved.
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